macro

Wegovy linked to lower 'food noise' in real-world telehealth data

Novo Nordisk reported ObesityWeek 2026 data where semaglutide users in the SIGNAL and OCTANE studies showed fewer intrusive food thoughts.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Novo Nordisk presented new real-world findings at ObesityWeek 2026, according to TradingView, which relayed the report from RTTNews and dpa-AFX. The data suggest that Wegovy, based on semaglutide, may ease so-called food noise, a term for persistent and unwanted thoughts about eating.

In the SIGNAL study, which covered more than 26,000 adults with obesity or overweight who had not previously been treated, self-reported food noise scores fell significantly within a month of starting the injectable form. The largest gains appeared in the first three months and held through six months. In the OCTANE study, patients on the oral version saw average scores drop by roughly 25% after three months, and 86.4% reported at least one improvement, such as better sleep, more energy and fewer alcohol cravings.

The company argued that the benefits may extend beyond weight loss. It also reminded readers of a boxed warning: the 2.4 mg injection and 25 mg tablet may raise the chance of thyroid growths, including cancer, and must not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

why it matters

For investors in Novo Nordisk (NVO), the report adds real-world evidence for semaglutide beyond weight reduction, a theme that matters in a competitive obesity-drug market. The results rely on self-reports and observation, so they do not on their own confirm a clinical effect, and the safety warning remains in place.

market impact

Novo Nordisk (NVO): new real-world data supports the case for semaglutide beyond weight loss

  • Novo Nordisk (NVO) pressure up — new real-world data widens the case for semaglutide's benefits beyond weight loss

tags

instruments

Novo Nordisk (NVO)

sources

  1. Novo Nordisk Says Wegovy May Help Reduce 'Food Noise' In Adults With Obesity — TradingView, 15 November 2026 at 02:40 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗